CTMX - CIK 0001501989
CytomX Therapeutics, Inc. (CTMX) reported revenue of $76.20M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $76.20M | -44.8% |
| FY 2024 | $138.10M | +36.4% |
| FY 2023 | $101.21M | +90.4% |
| FY 2022 | $53.16M | +42.5% |
| FY 2021 | $37.31M | -45.5% |
| FY 2020 | $68.43M | +154.4% |
| FY 2019 | $26.90M | -54.8% |
| FY 2018 | $59.50M | -16.9% |
| FY 2017 |
CytomX Therapeutics, Inc. (CTMX) reported revenue of $76.20M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2013 and fiscal 2025, CytomX Therapeutics, Inc.'s revenue grew from $888.00K to $76.20M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $71.62M |
| +376.1% |
| FY 2016 | $15.04M | +95.1% |
| FY 2015 | $7.71M | +51.9% |
| FY 2014 | $5.08M | +471.7% |
| FY 2013 | $888.00K | - |